Thermo Fisher Scientific Inc. $TMO Shares Sold by Baxter Bros Inc.

Baxter Bros Inc. trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,223 shares of the medical research company’s stock after selling 1,414 shares during the period. Thermo Fisher Scientific accounts for approximately 1.3% of Baxter Bros Inc.’s investment portfolio, making the stock its 23rd biggest holding. Baxter Bros Inc.’s holdings in Thermo Fisher Scientific were worth $11,139,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Beacon Financial Strategies CORP acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $29,000. Olistico Wealth LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $29,000. JPL Wealth Management LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter worth about $28,000. Highline Wealth Partners LLC grew its position in Thermo Fisher Scientific by 126.9% during the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after purchasing an additional 33 shares during the period. Finally, Cloud Capital Management LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter worth about $31,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have weighed in on TMO. Citigroup increased their price target on Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Robert W. Baird set a $653.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. UBS Group reissued a “neutral” rating and set a $615.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Finally, Barclays lowered their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $631.25.

Thermo Fisher Scientific Trading Down 3.0%

Shares of Thermo Fisher Scientific stock opened at $515.88 on Friday. The firm has a market capitalization of $191.71 billion, a PE ratio of 29.08, a P/E/G ratio of 2.85 and a beta of 0.97. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $643.99. The firm’s 50-day moving average price is $501.94 and its 200 day moving average price is $549.89. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, beating analysts’ consensus estimates of $6.45 by $0.12. The firm had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. Thermo Fisher Scientific’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period last year, the company posted $6.10 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were given a dividend of $0.47 per share. The ex-dividend date was Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.60%.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the sale, the executive vice president owned 20,752 shares in the company, valued at $11,230,982.40. This trade represents a 1.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at $63,499,170. This represents a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.